{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:18:06Z","timestamp":1775099886793,"version":"3.50.1"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Crohn\u2019s disease (CD) is associated with reduced quality of life, increased absenteeism and high direct medical costs resulting from frequent hospitalizations and surgeries. Tumor necrosis factor\u2013alpha inhibitors (TNFi\u2019s) have transformed the therapeutic landscape and enabled a shift from a symptom control to a treat-to-target strategy. The Effect of Tight Control Management on Crohn\u2019s Disease (CALM) trial demonstrated tight control (TC), with TNFi dose changes informed by biochemical markers of inflammation, achieved higher mucosal healing rates compared with conventional management (CM) based on symptoms. A Markov model compared TC and CM strategies from the perspective of the Canadian public payer using patient-observation data from the CALM trial. A regression model estimated weekly CD Activity Index\u2013based transition matrices over a 5-year horizon and included covariates to improve extrapolation of outcomes beyond the 48-week trial assessment period. Costs of CD-related hospitalizations, biomarker tests and adalimumab injections were sourced from public data. Other direct medical costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated. Absenteeism was monetized and included in a sensitivity analysis. Over the 5-year time horizon, TC reduced hospitalization costs by 64% compared with CM. Other direct medical costs were reduced by 22%; adalimumab costs increased by 38%, generating an ICER of $35,168 per QALY gained. Absenteeism costs were reduced by 54%, and, when that was included in the model, TC became dominant compared with CM. Management of CD with TC is cost-effective compared with CM in Canada and is dominant if indirect costs associated with absenteeism are included. Trial registration number: NCT01235689.<\/jats:p>","DOI":"10.1093\/jcag\/gwac001","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T20:14:20Z","timestamp":1643228060000},"page":"169-176","source":"Crossref","is-referenced-by-count":8,"title":["Cost-Effectiveness of Tight Control for Crohn\u2019s Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective"],"prefix":"10.1093","volume":"5","author":[{"given":"Peter L","family":"Lakatos","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, McGill University , Montreal, Quebec , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-0556","authenticated-orcid":false,"given":"Gilaad G","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology and Hepatology, University of Calgary , Calgary, Alberta , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Bressler","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, University of British Columbia , Vancouver, British Columbia , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8679-2541","authenticated-orcid":false,"given":"Reena","family":"Khanna","sequence":"additional","affiliation":[{"name":"London Health Sciences Centre\u2014University Campus , London, Ontario , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4366-9076","authenticated-orcid":false,"given":"Laura","family":"Targownik","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital, Joseph and Wolf Lebovic Health Complex , Toronto, Ontario , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Jones","sequence":"additional","affiliation":[{"name":"QEII\u2014Victoria Building , Halifax, Nova Scotia , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmine","family":"Rahal","sequence":"additional","affiliation":[{"name":"AbbVie Corporation , Saint-Laurent, Quebec , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"McHugh","sequence":"additional","affiliation":[{"name":"AbbVie Corporation , Saint-Laurent, Quebec , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology and Hepatology, University of Calgary , Calgary, Alberta , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"issue":"5","key":"2022080109000543500_CIT0001","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1053\/j.gastro.2019.01.002","article-title":"Past and future burden of inflammatory bowel diseases based on modeling of population-based data.","volume":"156","author":"Coward","year":"2019","journal-title":"Gastroenterology"},{"issue":"10114","key":"2022080109000543500_CIT0002","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies.","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"issue":"Suppl 1","key":"2022080109000543500_CIT0003","first-page":"1","article-title":"The impact of inflammatory bowel disease in Canada 2018: A scientific report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn\u2019s and Colitis Canada.","volume":"2","author":"Benchimol","year":"2019","journal-title":"J Can Assoc Gastroenterol"},{"issue":"10","key":"2022080109000543500_CIT0004","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/apt.14338","article-title":"Review article: Changes in the epidemiology of inflammatory bowel disease-clues for aetiology.","volume":"46","author":"Bernstein","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"2022080109000543500_CIT0005","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/jcag\/gwy048","article-title":"The impact of inflammatory bowel disease in Canada 2018: Quality of life.","volume":"2","author":"Jones","year":"2019","journal-title":"J Can Assoc Gastroenterol"},{"issue":"2","key":"2022080109000543500_CIT0006","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10620-014-3368-z","article-title":"The economic and quality-of-life burden of Crohn\u2019s disease in Europe and the United States, 2000 to 2013: A systematic review.","volume":"60","author":"Floyd","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"9","key":"2022080109000543500_CIT0007","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1136\/gutjnl-2014-307983","article-title":"Predictors and risks for death in a population-based study of persons with IBD in Manitoba.","volume":"64","author":"Bernstein","year":"2015","journal-title":"Gut"},{"issue":"2","key":"2022080109000543500_CIT0008","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult Crohn\u2019s disease in population-based cohorts.","volume":"105","author":"Peyrin-Biroulet","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2022080109000543500_CIT0009","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1365-2036.2008.03753.x","article-title":"Review article: Treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease.","volume":"28","author":"Panaccione","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"23","key":"2022080109000543500_CIT0010","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.3748\/wjg.v21.i23.7272","article-title":"Prevalence and predictors of hospitalization in Crohn\u2019s disease in a prospective population-based inception cohort from 2000-2012.","volume":"21","author":"Golovics","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"11","key":"2022080109000543500_CIT0011","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/ajg.2014.297","article-title":"Cumulative incidence of second intestinal resection in Crohn\u2019s disease: A systematic review and meta-analysis of population-based studies.","volume":"109","author":"Frolkis","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2022080109000543500_CIT0012","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ibd.21417","article-title":"Long-term complications, extraintestinal manifestations, and mortality in adult Crohn\u2019s disease in population-based cohorts.","volume":"17","author":"Peyrin-Biroulet","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"2022080109000543500_CIT0013","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1136\/gut.2004.041616","article-title":"Cost of illness of inflammatory bowel disease in the UK: A single centre retrospective study.","volume":"53","author":"Bassi","year":"2004","journal-title":"Gut"},{"issue":"8","key":"2022080109000543500_CIT0014","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/ibd.21878","article-title":"Direct medical cost of managing IBD patients: A Canadian population-based study.","volume":"18","author":"Bernstein","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"2022080109000543500_CIT0015","doi-asserted-by":"crossref","first-page":"e0227635","DOI":"10.1371\/journal.pone.0227635","article-title":"Patient preferences for maintenance therapy in Crohn\u2019s disease: A discrete-choice experiment.","volume":"15","author":"Hazlewood","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"2022080109000543500_CIT0016","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.gastro.2014.10.011","article-title":"Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn\u2019s disease: A network meta-analysis.","volume":"148","author":"Hazlewood","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"2022080109000543500_CIT0017","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/gutjnl-2019-318440","article-title":"Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: A population-based interrupted time series study.","volume":"69","author":"Murthy","year":"2020","journal-title":"Gut"},{"issue":"1","key":"2022080109000543500_CIT0018","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: The CHARM trial.","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"issue":"5","key":"2022080109000543500_CIT0019","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1053\/j.gastro.2008.07.069","article-title":"Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn\u2019s disease: Results from the CHARM study.","volume":"135","author":"Feagan","year":"2008","journal-title":"Gastroenterology"},{"issue":"9317","key":"2022080109000543500_CIT0020","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: The ACCENT I randomised trial.","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"9","key":"2022080109000543500_CIT0021","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease.","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"2022080109000543500_CIT0022","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/apt.15685","article-title":"Systematic review and meta-analysis: Efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn\u2019s disease.","volume":"51","author":"Ungaro","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"2022080109000543500_CIT0023","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1053\/j.gastro.2008.09.012","article-title":"Direct health care costs of Crohn\u2019s disease and ulcerative colitis in US children and adults.","volume":"135","author":"Kappelman","year":"2008","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"2022080109000543500_CIT0024","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jcag\/gwy055","article-title":"The impact of inflammatory bowel disease in Canada 2018: Direct costs and health services utilization.","volume":"2","author":"Kuenzig","year":"2019","journal-title":"J Can Assoc Gastroenterol"},{"issue":"1","key":"2022080109000543500_CIT0025","doi-asserted-by":"crossref","first-page":"128","DOI":"10.14309\/ajg.0000000000000503","article-title":"Longitudinal trends in the direct costs and health care utilization ascribable to inflammatory bowel disease in the biologic era: Results from a Canadian population-based analysis.","volume":"115","author":"Targownik","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2022080109000543500_CIT0026","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/14712598.2017.1287170","article-title":"Top-down approach to biological therapy of Crohn\u2019s disease.","volume":"17","author":"Hirschmann","year":"2017","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"2022080109000543500_CIT0027","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target.","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2022080109000543500_CIT0028","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/jcag\/gwz019","article-title":"Canadian Association of Gastroenterology Clinical Practice Guideline for the management of luminal Crohn\u2019s disease.","volume":"2","author":"Panaccione","year":"2019","journal-title":"J Can Assoc Gastroenterol"},{"issue":"10114","key":"2022080109000543500_CIT0029","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): A multicentre, randomised, controlled phase 3 trial.","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"2022080109000543500_CIT0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.gastro.2020.03.039","article-title":"Deep remission at 1 year prevents progression of early Crohn\u2019s disease.","volume":"159","author":"Ungaro","year":"2020","journal-title":"Gastroenterology"},{"issue":"4","key":"2022080109000543500_CIT0031","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/gutjnl-2019-318256","article-title":"Tight control for Crohn\u2019s disease with adalimumab-based treatment is cost-effective: An economic assessment of the CALM trial.","volume":"69","author":"Panaccione","year":"2020","journal-title":"Gut"},{"key":"2022080109000543500_CIT0032","year":"2020"},{"issue":"4","key":"2022080109000543500_CIT0033","doi-asserted-by":"crossref","first-page":"e027043","DOI":"10.1136\/bmjopen-2018-027043","article-title":"Cost-effectiveness of faecal calprotectin used in primary care in the diagnosis of inflammatory bowel disease.","volume":"9","author":"Zhang","year":"2019","journal-title":"BMJ Open"},{"key":"2022080109000543500_CIT0034","year":"2021"},{"key":"2022080109000543500_CIT0035","year":"2021"},{"key":"2022080109000543500_CIT0036","year":"2020"},{"key":"2022080109000543500_CIT0037"},{"key":"2022080109000543500_CIT0038","year":"2021"},{"key":"2022080109000543500_CIT0039","year":"2019"},{"key":"2022080109000543500_CIT0040","year":"2021"},{"key":"2022080109000543500_CIT0041","volume-title":"CADTH Health Technology Assessments. Comparative Value of Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP) Testing in Combination Versus Individually for the Diagnosis of Undifferentiated Patients with Suspected Inflammatory Disease or Serious Infection: A Systematic Review and Economic Analysis","author":"Assasi","year":"2015"},{"key":"2022080109000543500_CIT0042","year":"2021"},{"key":"2022080109000543500_CIT0043"},{"key":"2022080109000543500_CIT0044"},{"issue":"2","key":"2022080109000543500_CIT0045","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.clinthera.2008.02.016","article-title":"Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn\u2019s disease.","volume":"30","author":"Reilly","year":"2008","journal-title":"Clin Ther"},{"key":"2022080109000543500_CIT0046","year":"2020"},{"issue":"3","key":"2022080109000543500_CIT0047","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1524-4733.2007.00171.x","article-title":"Mapping from disease-specific measures to utility: An analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn\u2019s Disease Activity Index in Crohn\u2019s disease and measures of utility.","volume":"10","author":"Buxton","year":"2007","journal-title":"Value Health"},{"issue":"2","key":"2022080109000543500_CIT0048","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","article-title":"The estimation of a preference-based measure of health from the SF-36.","volume":"21","author":"Brazier","year":"2002","journal-title":"J Health Econ"},{"issue":"9","key":"2022080109000543500_CIT0049","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/hec.866","article-title":"A comparison of the EQ-5D and SF-6D across seven patient groups.","volume":"13","author":"Brazier","year":"2004","journal-title":"Health Econ"},{"key":"2022080109000543500_CIT0050","year":"2017"},{"key":"2022080109000543500_CIT0051","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"issue":"Suppl 1","key":"2022080109000543500_CIT0052","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/jcag\/gwy054","article-title":"The impact of inflammatory bowel disease in Canada 2018: Epidemiology.","volume":"2","author":"Kaplan","year":"2019","journal-title":"J Can Assoc Gastroenterol"},{"key":"2022080109000543500_CIT0053"},{"key":"2022080109000543500_CIT0054","author":"HADLIMA","year":"2018"},{"issue":"3","key":"2022080109000543500_CIT0055","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2036.2009.04033.x","article-title":"Cost-effectiveness of biological therapy for Crohn\u2019s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data.","volume":"30","author":"Bodger","year":"2009","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of the Canadian Association of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/5\/4\/169\/45042301\/gwac001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/5\/4\/169\/45042301\/gwac001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T09:02:25Z","timestamp":1700125345000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcag\/article\/5\/4\/169\/6546456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,3,10]]},"published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jcag\/gwac001","relation":{},"ISSN":["2515-2084","2515-2092"],"issn-type":[{"value":"2515-2084","type":"print"},{"value":"2515-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,3,10]]}}}